$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021022803 Filed on November 10, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.623M	$3.106M	$3.380M
YoY Change	-24.73%	-8.11%	-23.87%
% of Gross Profit
Research & Development	$4.715M	$4.630M	$4.271M
YoY Change	27.78%	8.41%	-41.56%
% of Gross Profit
Depreciation & Amortization	$102.0K	$107.0K	$81.00K
YoY Change	175.68%	32.1%	170.0%
% of Gross Profit
Operating Expenses	$7.338M	$4.630M	$4.271M
YoY Change	2.24%	8.41%	-41.56%
Operating Profit		$7.736M	$5.434M
YoY Change		42.36%	-146.24%
Interest Expense	-$338.0K	$437.0K	$0.00
YoY Change	8350.0%		-100.0%
% of Operating Profit		5.65%	0.0%
Other Income/Expense, Net	-$103.0K	-$374.0K	-$310.0K
YoY Change	-43.09%	20.65%	158.33%
Pretax Income	-$7.779M	-$8.110M	-$6.374M
YoY Change	5.66%	27.24%	-45.19%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$28.30M	-$8.110M	-$5.431M
YoY Change	284.43%	49.33%	-53.31%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.21
Diluted Earnings Per Share	-$1.121M	-$1.207M	-$5.032M
COMMON SHARES
Basic Shares Outstanding	6.910M shares	6.721M shares	521.4K shares
Diluted Shares Outstanding		6.718M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.83M	$59.72M	$43.21M
YoY Change	175.39%	38.19%	-8.45%
Cash & Equivalents	$51.83M	$59.72M	$18.82M
Short-Term Investments
Other Short-Term Assets	$553.0K	$701.0K	$2.633M
YoY Change	837.29%	-73.38%	-49.37%
Inventory
Prepaid Expenses	$949.0K	$1.300M
Receivables
Other Receivables
Total Short-Term Assets	$68.96M	$62.56M	$19.83M
YoY Change	247.86%	215.55%	-63.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.113M	$1.116M	$1.110M
YoY Change	0.27%	0.54%	-69.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$111.0K	$112.0K	$51.00K
YoY Change	117.65%	119.61%	-96.08%
Total Long-Term Assets	$4.275M	$4.585M	$3.038M
YoY Change	40.72%	50.92%	-36.71%
TOTAL ASSETS
Total Short-Term Assets	$68.96M	$62.56M	$19.83M
Total Long-Term Assets	$4.275M	$4.585M	$3.038M
Total Assets	$73.24M	$67.14M	$22.86M
YoY Change	220.33%	193.67%	-60.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$991.0K	$2.380M	$1.071M
YoY Change	-7.47%	122.22%	-60.33%
Accrued Expenses	$1.589M	$1.658M	$665.0K
YoY Change	138.95%	149.32%	-91.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$222.0K
YoY Change			11.0%
Total Short-Term Liabilities	$20.03M	$6.203M	$3.222M
YoY Change	521.54%	92.52%	-69.31%
LONG-TERM LIABILITIES
Long-Term Debt	$15.07M	$15.01M	$0.00
YoY Change	24603.28%		-100.0%
Other Long-Term Liabilities	$2.026M	$2.398M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$15.07M	$15.01M	$0.00
YoY Change	24603.28%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.03M	$6.203M	$3.222M
Total Long-Term Liabilities	$15.07M	$15.01M	$0.00
Total Liabilities	$37.12M	$23.61M	$4.949M
YoY Change	650.07%	376.99%	-67.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$100.1M	-$92.28M	-$71.76M
YoY Change	39.44%	28.6%
Common Stock	$7.000K	$7.000K	$15.00K
YoY Change	600.0%	-53.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.12M	$43.54M	-$64.65M
YoY Change
Total Liabilities & Shareholders Equity	$73.24M	$67.14M	$22.86M
YoY Change	220.33%	193.67%	-60.92%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$28.30M	-$8.110M	-$5.431M
YoY Change	284.43%	49.33%	-53.31%
Depreciation, Depletion And Amortization	$102.0K	$107.0K	$81.00K
YoY Change	175.68%	32.1%	170.0%
Cash From Operating Activities	-$7.985M	-$11.79M	-$7.102M
YoY Change	50.58%	66.0%	-15.05%
INVESTING ACTIVITIES
Capital Expenditures	-$27.00K	-$24.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$38.00K	$0.00
YoY Change
Cash From Investing Activities	-$27.00K	$14.00K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.000K	3.167M	-63.00K
YoY Change	-85.94%	-5126.98%	-152.5%
NET CHANGE
Cash From Operating Activities	-7.985M	-11.79M	-7.102M
Cash From Investing Activities	-27.00K	14.00K	0.000
Cash From Financing Activities	-9.000K	3.167M	-63.00K
Net Change In Cash	-8.021M	-8.608M	-7.165M
YoY Change	49.45%	20.14%	-13.99%
FREE CASH FLOW
Cash From Operating Activities	-$7.985M	-$11.79M	-$7.102M
Capital Expenditures	-$27.00K	-$24.00K	$0.00
Free Cash Flow	-$7.958M	-$11.77M	-$7.102M
YoY Change	50.07%	65.66%	-15.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y4M24D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35890
	dei	Entity Registrant Name EntityRegistrantName	Tempest Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1472564
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	(415)
	dei	Local Phone Number LocalPhoneNumber	798-8589
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	TPST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6910324	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59716000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18820000	USD
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	45000	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2796000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1005000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	62557000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	19825000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1110000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3357000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1877000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	112000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51000	USD
CY2021Q3	us-gaap	Assets Assets	67142000	USD
CY2020Q3	us-gaap	Assets Assets	22863000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2380000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1071000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1658000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	665000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1411000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	712000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	664000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	695000	USD
CY2021Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	89000	USD
CY2020Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	0	USD
CY2021Q3	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	1000	USD
CY2020Q3	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	79000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6203000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3222000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	820000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2398000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1727000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	23606000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	4949000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	114686731	shares
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	86707000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	196000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6900731	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	527265	shares
CY2021Q3	tpst	Common Stock Shares Subject To Repurchase Shares CommonStockSharesSubjectToRepurchaseShares	136	shares
CY2020Q4	tpst	Common Stock Shares Subject To Repurchase Shares CommonStockSharesSubjectToRepurchaseShares	29041	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135902000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2953000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-89000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92284000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71761000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43536000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-68793000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67142000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22863000	USD
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4630000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4271000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12451000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11392000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3106000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1163000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7197000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3583000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7736000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	5434000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	19648000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	14975000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	437000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	944000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	63000	USD
CY2020Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	3000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	69000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	87000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-8110000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-5431000	USD
	us-gaap	Profit Loss ProfitLoss	-20523000	USD
	us-gaap	Profit Loss ProfitLoss	-14888000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-31.91
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6717655	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	484085	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2739602	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	466495	shares
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8199000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5431000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20612000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14888000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	48114000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-89000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	USD
CY2021Q3	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	37000	USD
CY2021Q3	tpst	Stock Issuance Costs StockIssuanceCosts	349000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3513000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	296000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-346000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	73000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8110000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	43536000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-59365000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	USD
CY2020Q3	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	37000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	92000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5431000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-64654000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-68793000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-89000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	98000	USD
	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	132000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	86707000	USD
	tpst	Stock Issuance Costs StockIssuanceCosts	349000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	33523000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	827000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-6420000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18001000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	73000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20523000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	43536000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-50365000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40000	USD
	tpst	Stock Issuance Costs StockIssuanceCosts	265000	USD
	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	237000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	322000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14888000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-64654000	USD
	us-gaap	Profit Loss ProfitLoss	-20523000	USD
	us-gaap	Profit Loss ProfitLoss	-14888000	USD
	us-gaap	Depreciation Depreciation	272000	USD
	us-gaap	Depreciation Depreciation	255000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	827000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	321000	USD
	tpst	Noncash Lease Expense NoncashLeaseExpense	589000	USD
	tpst	Noncash Lease Expense NoncashLeaseExpense	394000	USD
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	516000	USD
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	-5000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-190000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	947000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1130000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-737000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-363000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	631000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	89000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-699000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	233000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17972000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14743000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	38000	USD
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	44000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	35000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	469000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33474000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	93000	USD
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	USD
	tpst	Payments Of Merger Related Cost Financing Activities PaymentsOfMergerRelatedCostFinancingActivities	-17045000	USD
	tpst	Payments Of Merger Related Cost Financing Activities PaymentsOfMergerRelatedCostFinancingActivities	0	USD
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	-6420000	USD
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-89000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	38000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59072000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34569000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40941000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19825000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3244000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59761000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23069000	USD
	us-gaap	Interest Paid Net InterestPaidNet	682000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	135000	USD
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	239000	USD
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5365899	shares
CY2021Q2	tpst	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0322
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, fair value of common stock stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="padding-left:18pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company’s products and processes and clinical efficacy and safety of the Company’s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company’s product candidates are still in development and, to date, none of the Company’s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the current COVID-19 (“coronavirus”) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the COVID-19 pandemic will impact the Company’s business will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div>
CY2020Q1	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	44000	USD
CY2020Q1	tpst	Note Receivable Related Party Vested Portion Repayment NoteReceivableRelatedPartyVestedPortionRepayment	43000	USD
CY2020Q1	tpst	Note Receivable Related Party Vested Accrued Interest Repayment NoteReceivableRelatedPartyVestedAccruedInterestRepayment	1000	USD
CY2021Q3	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	38000	USD
CY2021Q3	tpst	Note Receivable Related Party Vested Portion Repayment NoteReceivableRelatedPartyVestedPortionRepayment	35000	USD
CY2021Q3	tpst	Note Receivable Related Party Vested Accrued Interest Repayment NoteReceivableRelatedPartyVestedAccruedInterestRepayment	3000	USD
CY2021Q2	tpst	Note Receivable Related Party Forgiven NoteReceivableRelatedPartyForgiven	278000	USD
CY2021Q3	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	0	USD
CY2020Q4	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	260000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1300000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	245000	USD
CY2021Q3	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	795000	USD
CY2020Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	441000	USD
CY2021Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	260000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	701000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	59000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2796000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1005000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1839000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1566000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	723000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	456000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1110000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	107000	USD
	us-gaap	Depreciation Depreciation	272000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	81000	USD
	us-gaap	Depreciation Depreciation	255000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1246000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	441000	USD
CY2021Q3	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	412000	USD
CY2020Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	224000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1658000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	665000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y8M12D
CY2019Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	9780	sqft
CY2021Q3	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	1000	USD
CY2020Q4	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	79000	USD
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	136	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	29041	shares
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q3	tpst	Number Of Non Cancelable Operating Lease Agreements NumberOfNonCancelableOperatingLeaseAgreements	2	lease
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	393000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1604000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1647000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	443000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4087000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	278000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3809000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1411000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2398000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15005000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5365899	shares
CY2021Q2	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6900731	shares
CY2021Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	136	shares
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	469202	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	489797	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
	tpst	Assumed In Reverse Recapitalization Share Based Compensation Arrangement By Share Based Payment Award Shares Assumed From Reverse Recapitalization AssumedInReverseRecapitalizationShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAssumedFromReverseRecapitalization	116509	shares
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod	177591	shares
	tpst	Share Based Compensation Arrangements By Share Based Payment Award Optionsassumed In Reverse Recapitalization In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice	179.79
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted	232669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232669	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.09
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25871	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.77
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled And Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledAndForfeited	95488	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100459	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	107.77
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	469125	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	736095	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	736095	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	736095	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	736095	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M13D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4124738	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4124738	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	735934	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	735934	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y7M13D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	37.48
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	37.48
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4123358	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4123358	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	306998	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	306998	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y25D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	72.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	72.78
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1792906	USD
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1792906	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	321000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	296000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	827000	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8110000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5431000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20523000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14888000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6721400	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	521408	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2751519	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	519047	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3745	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	37323	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	11917	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	52552	shares
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6717655	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	484085	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2739602	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	466495	shares
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-31.91
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	742131	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4077577	shares

Files In Submission

Name	View Source	Status
0001628280-21-022803-index-headers.html	Edgar Link	pending
0001628280-21-022803-index.html	Edgar Link	pending
0001628280-21-022803.txt	Edgar Link	pending
0001628280-21-022803-xbrl.zip	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpst-20210930.htm	Edgar Link	pending
tpst-20210930.xsd	Edgar Link	pending
tpst-20210930_cal.xml	Edgar Link	unprocessable
tpst-20210930_def.xml	Edgar Link	unprocessable
tpst-20210930_htm.xml	Edgar Link	completed
tpst-20210930_lab.xml	Edgar Link	unprocessable
tpst-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2021 Q4 Form 10-Q Financial Statement

#000162828021022803 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2021 Q4 Form 10-Q Financial Statement

#000162828021022803 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst